Patents by Inventor Bertrand Le Bourdonnec

Bertrand Le Bourdonnec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and uses thereof
    Patent number: 12268687
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: April 8, 2025
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona Wrona, Kerem Ozboya, Matthew Lucas, Bhaumik Pandya, Bertrand Le Bourdonnec
  • COMPOUNDS AND USES THEREOF
    Publication number: 20250034124
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: January 30, 2025
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • COMPOUNDS AND USES THEREOF
    Publication number: 20250034125
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: January 30, 2025
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • Compounds and uses thereof
    Patent number: 12180221
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: December 31, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Bertrand Le Bourdonnec, Matthew Lucas, Kerem Ozboya, Bhaumik Pandya, Parcharee Tivitmahaisoon, Iwona Wrona
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240400546
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: April 29, 2024
    Publication date: December 5, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Iwona WRONA
  • GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240376058
    Abstract: Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Application
    Filed: January 10, 2024
    Publication date: November 14, 2024
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
  • Compounds and uses thereof
    Patent number: 12098146
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 24, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona Wrona, Kerem Ozboya, Matthew Lucas, Bhaumik Pandya, Bertrand Le Bourdonnec
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240300938
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: April 29, 2024
    Publication date: September 12, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Iwona WRONA
  • PYRIDOPYRIMIDINES AND METHODS OF THEIR USE
    Publication number: 20240208964
    Abstract: Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: June 27, 2024
    Inventors: Kerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
  • PURINES AND METHODS OF THEIR USE
    Publication number: 20240150358
    Abstract: Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: May 9, 2024
    Inventors: Kerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
  • ULK INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240150368
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: August 28, 2023
    Publication date: May 9, 2024
    Inventors: Justin T. Proto, Andrew Michael Harned, Kristen Stoltz, Timothy Caldwell, Lakshminarayana Vogeti, Yu Mi Ahn, Bertrand Le Bourdonnec, Daniel L. Flynn
  • Compounds and uses thereof
    Patent number: 11970486
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bertrand Le Bourdonnec, Matthew Lucas, Kerem Ozboya, Bhaumik Pandya, Parcharee Tivitmahaisoon, Iwona Wrona
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240124435
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 18, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • GCN2 and perk kinase inhibitors and methods of use thereof
    Patent number: 11912668
    Abstract: Described herein are compounds, such as compounds represented by Formula I-R: and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
  • Compounds and uses thereof
    Patent number: 11873298
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: January 16, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • RAF KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230357179
    Abstract: Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
  • AMINO ALCOHOL COMPOUNDS AND USES THEREOF
    Publication number: 20230339890
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: June 3, 2021
    Publication date: October 26, 2023
    Inventors: Iwona WRONA, Kerem OZBOYA, Bertrand LE BOURDONNEC, Vanessa KURIA, Madeline MACDONNELL, Matthew LUCAS, Byron DELABARRE
  • BICYCLIC HETEROARENES AND METHODS OF THEIR USE
    Publication number: 20230271965
    Abstract: Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: August 31, 2023
    Inventors: Kerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
  • RAF KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230257352
    Abstract: Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 9, 2022
    Publication date: August 17, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230116101
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: November 13, 2020
    Publication date: April 13, 2023
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC